Clinical Trial to Compare the Pharmacokinetics of DP-R208

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

A randomized, single-dose, open, crossover clinical trial to compare the pharmacokinetics of DP-R208 (Candesartan cilexetil and Rosuvastatin calcium fixed dose combinations) in comparison to each component administered alone in healthy male volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alvogen Korea
• Treatments: Candesartan; Candesartan cilexetil; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• BMI 17.5~30.5

• signed the informed consent form prior to the study participation

Exclusion Criteria:

• Clinically significant disease

• Previously donate whole blood within 60 days or component blood within 14 days

• Clinically significant allergic disease

• Taken IP in other trial within 90 days

• An impossible one who participates in clinical trial by investigator's decision including laboratory test result